Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.76 USD | +3.70% | -3.76% | -31.91% |
15/04 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
25/03 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Business Summary
Number of employees: 526
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Genome Editing-based Therapies
100.0
%
| 52 | 100.0 % | 36 | 100.0 % | -30.40% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 52 | 100.0 % | 36 | 100.0 % | -30.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 66 | 01/14/01 |
Glenn Goddard
DFI | Director of Finance/CFO | 53 | 29/18/29 |
Eliana Clark
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
Chief Tech/Sci/R&D Officer | 63 | 28/19/28 | |
David Lebwohl
CTO | Chief Tech/Sci/R&D Officer | 69 | 30/20/30 |
Li Lina
IRC | Investor Relations Contact | - | - |
- | - | ||
Aron Stein
LAW | General Counsel | - | - |
Derek Hicks
PRN | Corporate Officer/Principal | 51 | 20/21/20 |
Marika St Amand
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Cohen
BRD | Director/Board Member | 67 | 24/19/24 |
John Leonard
CEO | Chief Executive Officer | 66 | 01/14/01 |
Frank Verwiel
CHM | Chairman | 62 | 24/17/24 |
William Chase
BRD | Director/Board Member | 57 | 14/23/14 |
Jesse Goodman
BRD | Director/Board Member | 72 | 31/18/31 |
Georgia Keresty
BRD | Director/Board Member | 62 | 09/21/09 |
Muna Bhanji
BRD | Director/Board Member | 61 | 28/22/28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 96,106,405 | 94,793,096 ( 98.63 %) | 0 | 98.63 % |
Company contact information
Intellia Therapeutics, Inc.
40 Erie Street Suite 130
02139, Cambridge
+857 285 6200
http://www.intelliatx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.91% | 2B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NTLA Stock
- Company Intellia Therapeutics, Inc.